Recent developments highlight ongoing regulatory engagement and clinical progress for Kezar's lead candidate, zetomipzomib, alongside financial and strategic updates.

• In January 2026, the FDA Division of Hepatology and Nutrition granted Kezar a Type C meeting to discuss development plans for zetomipzomib in autoimmune hepatitis, focusing on a potential global Phase 2b trial [N1].
• In March 2026, Kezar completed a successful Type C meeting with the FDA, receiving constructive feedback and agreement on treatment duration, endpoints, enrollment criteria, and safety monitoring for zetomipzomib development in AIH [S1].
• In October 2025, Kezar announced plans to explore strategic alternatives and implemented a workforce reduction of approximately 70% amid challenges with FDA alignment on registrational trials [S1].
• In July 2025, the FDA lifted a partial clinical hold on the Phase 2a trial of zetomipzomib in autoimmune hepatitis, allowing the trial to proceed [N4].
• In Q2 2025, Kezar reported a 37% reduction in net loss compared to prior periods, reflecting cost management and restructuring efforts [N3].
• Wells Fargo maintained an equal-weight recommendation on Kezar in October 2025, reflecting a neutral stance on the company's prospects amid ongoing developments [N2].
• Kezar's stock experienced a trading halt in October 2024 pending news, indicating periods of market uncertainty [N7].

Kezar's lead candidate, zetomipzomib, has shown encouraging clinical activity and a favorable safety profile in Phase 1b/2 trials for systemic lupus erythematosus and autoimmune hepatitis, including steroid sparing effects in refractory AIH patients. The recent constructive FDA Type C meeting provides clarity on regulatory pathways, endpoints, and safety monitoring, potentially enabling a feasible registrational trial. The company's strong patent portfolio and licensing agreements support potential commercial opportunities across multiple immune-mediated diseases. The company's strong liquidity position supports ongoing development and strategic initiatives.

Kezar has faced significant regulatory challenges, including FDA clinical holds and termination of the PALIZADE Phase 2b trial due to serious adverse events and fatalities. The company has no approved products and has incurred substantial operating losses with an accumulated deficit nearing $476 million. The ongoing restructuring and exploration of strategic alternatives reflect uncertainty about the company's ability to continue as a going concern. Clinical development risks, potential safety issues, and competitive pressures in the immunology space pose material risks to the company's future prospects.

Kezar's moat is based on its proprietary selective immunoproteasome inhibitor, zetomipzomib, which is the only agent to demonstrate steroid sparing clinical activity in refractory autoimmune hepatitis patients. The company holds exclusive licensing rights from Onyx Therapeutics with patent protection extending to at least 2034, and has established collaborations for commercialization in Asia. The unique mechanism targeting multiple immune regulators with a favorable safety profile differentiates it from existing therapies that target single cytokines or broadly suppress the immune system. However, as a clinical-stage company without approved products, the moat is contingent on successful clinical development, regulatory approval, and commercialization.

• Clinical Development Risk: Kezar's lead product candidate, zetomipzomib, is in early clinical stages with limited patient data. Past trials have faced clinical holds and serious adverse events, including fatalities, which may impact future development and regulatory approval.
• Regulatory Risk: The company has experienced challenges aligning with the FDA on registrational trial designs, leading to restructuring and strategic alternatives. Regulatory feedback and requirements may delay or limit development progress.
• Financial Risk: Kezar has incurred significant losses since inception with no product revenues. Continued operating losses and the need for additional financing pose risks to sustaining operations and funding development programs.
• Competitive Risk: The biotechnology and pharmaceutical sectors are highly competitive with many companies developing therapies for immune-mediated diseases. Competitors may have greater resources and more advanced products.
• Manufacturing and Supply Risk: Kezar relies entirely on third-party contract manufacturing organizations for clinical and potential commercial supply, which may pose risks related to quality, capacity, and regulatory compliance.

• Kezar Life Sciences, Inc. is a clinical-stage biotechnology company developing novel small molecule therapeutics targeting immune-mediated diseases, focusing on a selective immunoproteasome inhibitor, zetomipzomib [S1].
• The company has been implementing a restructuring plan and exploring strategic alternatives since October 2025 after challenges aligning with the FDA on a registrational trial for zetomipzomib in autoimmune hepatitis (AIH) [S1].
• Zetomipzomib is the only investigational agent to have demonstrated steroid sparing clinical activity in AIH patients refractory or intolerant to standard therapies [S1].
• The FDA granted a Type C meeting in January 2026 to discuss a potential global randomized Phase 2b trial of zetomipzomib in relapsed and refractory AIH, with constructive feedback received in March 2026 including agreement on treatment duration, endpoints, enrollment criteria, and safety monitoring [S1][N1].
• Zetomipzomib has completed Phase 1a studies in healthy volunteers and Phase 1b/2 MISSION trial in systemic lupus erythematosus (SLE) and lupus nephritis (LN), showing encouraging clinical activity and favorable safety [S1].
• The PALIZADE Phase 2b trial in LN was terminated in 2024 after FDA clinical hold due to serious adverse events including fatalities; the safety profile was similar across dose levels [S1].
• The PORTOLA Phase 2a trial in AIH showed that 50% of patients on zetomipzomib achieved complete biochemical remission (CR) by week 25 compared to 37.5% on placebo, with higher rates of steroid taper and steroid-free remission in the treatment arm [S1].
• Treatment-emergent adverse events were common, with injection site reactions most frequent; serious adverse events were few and considered unrelated to treatment [S1].
• The company has licensing agreements with Onyx Therapeutics (Amgen subsidiary) for immunoproteasome inhibitors excluding oncology uses, with patent coverage extending to at least 2034, and Everest Medicines for Greater China and select Asian territories with upfront and milestone payments plus royalties [S1].
• Kezar does not own manufacturing facilities and relies on third-party contract manufacturing organizations (CMOs) compliant with cGMP for clinical trial materials; plans to contract for commercial production if approved [S1].
• The company has no product sales and has incurred operating losses since inception, with an accumulated deficit of $476 million as of September 30, 2025 [S2].
• As of December 31, 2025, Kezar had cash and cash equivalents of approximately $71.9 million, current assets of $75.7 million, current liabilities of $6.6 million, resulting in a current ratio of 11.52 and a cash ratio of 10.93, indicating strong liquidity [S1][S2].
• Net loss for the fiscal year ended December 31, 2025 was $56.0 million with basic and diluted EPS of -$7.66 per share [S1].
• The company reduced workforce by approximately 70% in November 2025 as part of strategic review and restructuring [S1].
• Recent news includes FDA granting a Type C meeting to discuss zetomipzomib development in AIH (Jan 2026), FDA lifting partial clinical hold on Phase 2a trial (July 2025), and narrowing of losses reported in Q2 2025 [N1][N3][N4].
• Wells Fargo maintained an equal-weight recommendation on Kezar in October 2025 [N2].
• Kezar's stock experienced a trading halt in October 2024 pending news [N7].